In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous article 71, which allows an early paid access.
Who else could better speak about the Swiss system with him than Remo Christen? Remo is working since > 20 years in the Swiss market access environment in a leading role at Roche’s Swiss affiliate.
In this episode, listeners will learn the specifics of the Swiss culture, the reimbursement process also in comparison to the German AMNOG and why Switzerland is attractive for drug launches.
Subscribe with your favorite podcasting platform.
For more information about MArS Market Access and Pricing Strategy visit: